E6005 in Pediatric Subjects With Atopic Dermatitis
Phase of Trial: Phase I/II
Latest Information Update: 01 Mar 2018
Price : $35 *
At a glance
- Drugs Lotamilast (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Inc
- 11 Mar 2015 Status changed from recruiting to complete, according to ClinicalTrials.gov record.
- 16 Jul 2014 Planned number of patients changed from 60 to 24 as reported by ClinicalTrials.gov.
- 25 Mar 2014 New trial record